News
The struggling Danish company says it looks to reorganize, with the impact on North Carolina workers still unclear.
22hon MSN
Novo Nordisk, maker of obesity drug Wegovy, to cut 9,000 jobs to sharpen focus, meet competition
FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk, maker of weight-loss drug Wegovy, said Wednesday it ...
Wegovy-maker Novo Nordisk will cut 9,000 jobs, or about 11.5% of its workforce, in a restructuring to save 8 billion Danish ...
1don MSN
Novo Nordisk says it's cutting 9,000 workers amid increased competition for its obesity drug Wegovy
Novo Nordisk said the job cuts will eliminate about 11% of its workforce, with 5,000 of the reductions in Denmark.
The maker of the popular weight-loss drug Wegovy announced on Wednesday that it will be cutting 9,000 jobs in the company.
Novo Nordisk, the Danish pharmaceutical giant behind weight-loss drug Wegovy and diabetes treatment Ozempic, announced plans to cut 9,000 jobs, or 11.5% of its global workforce, as part of a major ...
Novo Nordisk is a sector leader in the fast-growing GLP-1 market, boasting strong fundamentals, a healthy balance sheet, and solid management. Recent stock weakness stems from sector-wide regulatory ...
Novo Nordisk A/S Q2 earnings were solid, but the guidance disappointed. My investment decision was based on a long-term outlook rather than this single quarter. Novo Nordisk's narrative shifted ...
Prescription savings platform GoodRx is collaborating with pharma giant Novo Nordisk to make Ozempic and Wegovy pens available to eligible self-paying patients using GoodRx for $499 per month at ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results